000			06235cam a2200913 i 4500
001			ocn904959309
003			OCoLC
005			20171224114844.0
006			m o d
007			cr |||||||||||
008			150408s2015 enk ob 001 0 eng
010			_a 2015014108
040			_aDLC _beng _erda _epn _cDLC _dN$T _dDG1 _dBTCTA _dIDEBK _dE7B _dCDX _dYDXCP _dCOO _dEBLCP _dRECBK _dOCLCF _dOCLCQ _dDEBBG _dK6U
019			_a905989856 _a961695642 _a962722672
020			_a9781118892565 _q(ePub)
020			_a1118892569 _q(ePub)
020			_a9781118892558 _q(Adobe PDF)
020			_a1118892550 _q(Adobe PDF)
020			_a9781118892572
020			_a1118892577
020			_a1118892542 _q(cloth)
020			_a9781118892541 _q(cloth)
020			_z9781118892541 _q(cloth)
029	1		_aCHBIS _b010442471
029	1		_aCHVBK _b334084547
029	1		_aDEBBG _bBV042793100
029	1		_aNZ1 _b16078501
029	1		_aDEBBG _bBV043397613
035			_a(OCoLC)904959309 _z(OCoLC)905989856 _z(OCoLC)961695642 _z(OCoLC)962722672
042			_apcc
050	0	0	_aRS431.A64
072		7	_aHEA _x039000 _2bisacsh
072		7	_aMED _x014000 _2bisacsh
072		7	_aMED _x022000 _2bisacsh
072		7	_aMED _x112000 _2bisacsh
072		7	_aMED _x045000 _2bisacsh
082	0	0	_a615.7/98 _223
084			_aSCI007000 _2bisacsh
049			_aMAIN
100	1		_aLednicer, Daniel, _d1929-
245	1	0	_aAntineoplastic drugs : _borganic syntheses / _cDaniel Lednicer.
264		1	_aChichester, West Sussex : _bJohn Wiley & Sons. Ltd, _c2015.
300			_a1 online resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
520			_a"Antineoplastic Drugs: Organic Syntheses is written to appeal to organic and medicinal chemists in industry and academia. It is beneficial to those composing grant proposals for NCI and related organizations"-- _cProvided by publisher.
504			_aIncludes bibliographical references and index.
588	0		_aPrint version record and CIP data provided by publisher.
505	0		_aTitle Page; Copyright Page; Contents; Preface; Introduction; Chapter 1 Alkylating Agents; 1.1 bis-Chloroethyl Amines; 1.2 Several Other Chloroethyl Agents; 1.3 Platinum-Based Antineoplastic Agents; 1.4 Miscellaneous Alkylating Agents; References; Chapter 2 Antimetabolites; 2.1 Introduction; 2.2 Folate Antagonists; 2.2.1 Compounds with Glutamate Side Chain; 2.2.2 Compounds Lacking the Glutamate Moiety; 2.2.3 Methoxylated Benzenes; 2.3 Pyrimidines and Purines; 2.3.1 Aglycones; 2.3.2 Saccharide-Linked Compounds; References; Chapter 3 Hormone Blocking Anticancer Drugs; 3.1 Introduction.
505	8		_a3.2 Estrogen Antagonists3.2.1 Estrogen Antagonists; 3.2.2 Aromatase Inhibitors; 3.3 Androgen Antagonists; 3.3.1 Non-steroidal Antian drogens; 3.3.2 Steroid Androgen Antagonists; References; Chapter 4 Topoisomerase Inhibitors; 4.1 Introduction; 4.2 Anthracyclines; 4.3 Anthraquinones and Anthrapyrazoles; 4.3.1 Anthraquinones with Two Aminoalkyl Side Chains; 4.3.2 Anthraquinones with a Fused Pyrazole Ring; 4.3.3 Heterocyclic Anthraquinones; 4.4 Camptothecins; 4.4.1 Compounds from Modified Camptothecin; 4.4.2 Camptothecins by Total Synthesis; 4.5 Miscellaneous Topoisomerase Inhibitors; References.
505	8		_aChapter 5 Mitotic Inhibitors5.1 Introduction; 5.2 Taxanes; 5.3 Wholly Synthetic Compounds; 5.3.1 Carbocyclic Compounds; 5.3.2 Peptide-Like Inhibitors; 5.3.3 Monocyclic Heterocyclic Inhibitors; 5.3.4 Bicyclic 5:6 Heterocyclic Inhibitors; 5.3.5 Bicyclic 6:6 Heterocyclic Tubulin Inhibitors; References; Chapter 6 Matrix Metalloproteinase Inhibitors; 6.1 Introduction; 6.2 Hydroxamates; 6.2.1 Agents with an Isobutyl Moiety; 6.2.2 A Thiomorpholine; 6.2.3 Sulfamates; 6.2.4 Miscellaneous Compounds; References; Chapter 7 Histone Deacetylase Inhibitors; 7.1 Introduction; 7.2 Hydroxamates.
505	8		_a7.3 PhenylenediaminesReferences; Chapter 8 Enzyme Inhibitor, Part I, Tyrosine Kinases; 8.1 Introduction; 8.2 Epidermal Growth Factor Inhibitors; 8.3 VEGF; 8.3.1 Fused Ring Compounds; 8.3.2 Linear Arrays; 8.4 SRC Nonreceptor Tyrosine Kinase; 8.5 PDGF; 8.6 EGF; 8.7 Other TKI; 8.7.1 Linear Arrays; 8.7.2 Compounds with Two Fused Rings; 8.8 Janus Kinase Inhibitors; References; Chapter 9 Enzyme Inhibitors: Part II Additional Targets; 9.1 Serine-Threonine Kinase Inhibitors; 9.2 Additional Enzyme Inhibitors; 9.2.1 Farnesyl Transferase Inhibitors; 9.2.2 Cyclin-Dependent Kinase Inhibitors.
505	8		_a9.2.3 Proteasome Inhibitors9.2.4 PARP Inhibitors; 9.2.5 Various Other Enzyme Inhibitors; References; Chapter 10 Miscellaneous Antineoplastic Agents; 10.1 Acyclic; 10.2 Monocyclic; 10.3 Two Linked Rings; 10.4 Rings on a Chain; 10.4.1 Two Rings; 10.4.2 Four and More Rings; 10.5 Fused Rings; 10.5.1 Indoles; 10.5.2 Purine-Like; 10.5.3 Tetralins and a Naphthalene; 10.5.4 Etc.; References; Appendix A; Index of Heterocycle Syntheses; Subject Index; EULA.
650		0	_aAntineoplastic agents.
650		0	_aDrugs _xSynthesis.
650		4	_aAntimetabolites.
650		4	_aAntineoplastic agents.
650		4	_aCancer.
650		4	_aDrugs _xAdministration.
650		4	_aPharmacognosy.
650		7	_aSCIENCE _xLife Sciences _xBiochemistry. _2bisacsh
650		7	_aAntineoplastic agents. _2fast _0(OCoLC)fst00810595
650		7	_aDrugs _xSynthesis. _2fast _0(OCoLC)fst00898936
655		4	_aElectronic books.
776	0	8	_iPrint version: _aLednicer, Daniel, 1929- _tAntineoplastic drugs. _dChichester, West Sussex : Wiley, 2015 _z9781118892541 _w(DLC) 2015008084
856	4	0	_uhttp://onlinelibrary.wiley.com/book/10.1002/9781118892572 _zWiley Online Library
938			_aBaker and Taylor _bBTCP _nBK0016346929
938			_aCoutts Information Services _bCOUT _n31089705
938			_aEBL - Ebook Library _bEBLB _nEBL1964101
938			_aebrary _bEBRY _nebr11032414
938			_aEBSCOhost _bEBSC _n966490
938			_aIngram Digital eBook Collection _bIDEB _ncis31089705
938			_aRecorded Books, LLC _bRECE _nrbeEB00607377
938			_aYBP Library Services _bYANK _n11419803
938			_aYBP Library Services _bYANK _n12340685
938			_aYBP Library Services _bYANK _n12673559
994			_a92 _bDG1
999			_c13955 _d13955